Table 2

Susceptibilities of the studied C. albicans strains to selected antifungal agents

Strain (background, genotype)MIC (μg/ml)a
Standard MIC assayEtestSupplementation
FLCITCVORPOSAmBAmBFLC + FBSbFLC + ergosterolc
SC5314 (ERG3/ERG3)0.250.0040.0040.0161.00.190.250.25
CAF2-1 (ERG3/ERG3)0.250.0040.0040.0161.00.19NTNT
DSY294 (ERG3/ERG3)0.1250.0040.0080.0161.00.19NTNT
DSY1751 (erg3/erg3)>128>16>16>161.00.25NTNT
VSY2 (erg3-1/erg3-1)>128>16>16>162.00.50>1280.25d
VSY18 (SC5314, erg3-1/erg3-1)>128>16>16>162.00.50>1280.25d
VSY19 (SC5314, ERG3-2/ERG3-2)0.50.0040.0040.0161.00.190.250.25
VSY20 (VSY2, ERG3-2/ERG3-2)0.250.0040.0040.0161.00.190.250.25
  • a Abbreviations: FLC, fluconazole; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; AmB, amphotericin B; NT, not tested.

  • b MICs were determined in RPMI 1640 medium supplemented with 10% (vol/vol) FBS.

  • c MICs were determined in RPMI 1640 medium supplemented with 20 μg/ml of ergosterol.

  • d High trailing growth, approaching 50% of that of the growth control throughout the full range of fluconazole concentrations (see Fig. S5 in the supplemental material).